^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PGR positive

    i
    Other names: PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
    Entrez ID:
    5241
    Related biomarkers:
    Expression
    Mutation
    Others
    3d
    Treatment pattern and preferences of locally advanced and metastatic HR+, HER2- breast cancer from a Chinese physician and patient survey (ChiCTR2600116892)
    P=N/A, N=320, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive
    3d
    Longitudinal Changes in the Vaginal Microbiome During Endocrine Therapy in Premenopausal Breast Cancer and Their Association with Genitourinary Syndrome of Menopause (GSM): A Single-Center Prospective Cohort Study. (ChiCTR2500115283)
    P=N/A, N=110, Not yet recruiting, Women's Hospital School of Medicine Zhejiang University; Women's Hospital School of Medicine Zhejiang University
    New trial
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PGR positive
    3d
    Efficacy and safety of Dalpiciclib in the treatment of hormone receptor-positive advanced breast cancer a multicenter observational real-world study (ChiCTR2500114023)
    P=N/A, N=500, Recruiting, Harbin Medical University Affiliated Cancer Hospital; Harbin Medical University Affiliated Cancer Hospital
    New trial
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • PGR positive
    |
    AiRuiKang (dalpiciclib)
    3d
    A Multicenter Randomized Controlled Clinical Trial of Neoadjuvant Endocrine Therapy versus Chemotherapy in Patients with HR+/HER2- Early-Stage Breast Cancer (ChiCTR2500111780)
    P4, N=148, Not yet recruiting, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    paclitaxel • cyclophosphamide • Kisqali (ribociclib) • letrozole • epirubicin • goserelin acetate
    10d
    TBCRC 050: Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer (clinicaltrials.gov)
    P1/2, N=46, Active, not recruiting, University of Alabama at Birmingham | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Nov 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    PGR (Progesterone receptor)
    |
    PGR positive • EGFR positive
    |
    Herceptin (trastuzumab) • Zejula (niraparib)
    12d
    REaCT-HER TIME: Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy (clinicaltrials.gov)
    P4, N=52, Active, not recruiting, Ottawa Hospital Research Institute | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PGR (Progesterone receptor)
    |
    HER-2 positive • PGR positive
    |
    Herceptin (trastuzumab)
    13d
    CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS) (clinicaltrials.gov)
    P3, N=1903, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HER-2 amplification • PGR positive
    |
    tamoxifen • letrozole • exemestane
    14d
    Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco) (clinicaltrials.gov)
    P2, N=334, Not yet recruiting, Fudan University
    New P2 trial • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • RAD51 (RAD51 Homolog A) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • FANCM (FA Complementation Group M) • RAD52 (RAD52 Homolog DNA Repair Protein) • RPA1 (Replication Protein A1) • PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    HER-2 negative • PALB2 mutation • PGR positive • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation
    |
    capecitabine • AiRuiYi (fluzoparib)
    17d
    MACS: Diet Modification in pAtients With Luminal Early Breast Cancer Candidate for Primary Surgery (clinicaltrials.gov)
    P=N/A, N=75, Recruiting, Institut du Cancer de Montpellier - Val d'Aurelle | Trial completion date: Apr 2026 --> Dec 2026 | Trial primary completion date: Apr 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive
    17d
    Solid Papillary Carcinoma of the Breast-A Case Treated with Total Mastectomy Following Preoperative Diagnosis of Mass-Forming Ductal Carcinoma (PubMed, Gan To Kagaku Ryoho)
    Postoperatively, the patient was started on tamoxifen, and she remains recurrence-free to date. This case underscoring the importance of careful pre-treatment assessment of malignancy.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • SYP (Synaptophysin)
    |
    ER positive • HER-2 amplification • PGR positive
    |
    tamoxifen
    17d
    Pleomorphic Invasive Lobular Carcinoma Developed after Surgery for Simultaneous Ipsilateral Multiple Cancers (PubMed, Gan To Kagaku Ryoho)
    The results were ER negative, PgR positive, HER2 negative, and Ki-67 25%. As the prognosis and treatment of invasive lobular carcinoma was unclear, caution was required.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative • PGR positive
    17d
    A Case of T4b Breast Cancer That Developed 17 Years after Radiofrequency Ablation (PubMed, Gan To Kagaku Ryoho)
    After that, trastuzumab+pertuzumab was administered 17 times. Currently, the patient is being followed up with fulvestrant. Two years after surgery, there has been no obvious metastasis or recurrence.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • PGR positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • fulvestrant